US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,222.35

-28.8992-2.31%

Number of Gainers:3

Number of Losers:4

Number of Flat:- -

PE:- -

High:1,257.62

Open:1,252.13

Low:1,216.60

Close:1,251.24

Loading ...

European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading

MT Newswires Live

Early notable gainers among liquid option names on April 17th

Eli Lilly rises 13.0%

Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025

Unusually active option classes on open April 17th

Eli Lilly Shares Soar 14% as Lilly Pill Leads To 7.9% Weight Loss In Late-Stage Trial

Shares of Some Obesity Drug Developers Fall After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial

THOMSON REUTERS

U.S.-Listed Shares of Novo Nordisk Down 7.9%, Viking Therapeutics Down 3.9%, Amgen Down 3.4%

THOMSON REUTERS

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial

THOMSON REUTERS

Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost. -- Barrons.com

Eli Lilly's Stock Soars 13% After Reporting Positive Data From Trial Of Diabetes And Weight-Loss Pill -- MarketWatch

Eli Lilly's stock soars 13% after reporting positive data from trial of diabetes and weight-loss pill

Novo Nordisk : Bmo Cuts to Market Perform From Outperform; Cuts Target Price to $64 From $105

THOMSON REUTERS

Eli Lilly announces ACHIEVE-1 trial met primary endpoint

Diabetes Device Maker Dexcom Shares Down 3.1% Premarket After Lilly's Pill Leads to Weight Loss in Late-Stage Trial

THOMSON REUTERS

Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell

MT Newswires Live

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

Eli Lilly - Expects to Submit Orforglipron for Weight Management, Submission for Treatment of Type 2 Diabetes Anticipated in 2026

THOMSON REUTERS

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4599/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1222.3358,"timestamp":1745263493490,"preClose":1251.235,"halted":0,"volume":44034291,"delay":0,"changeRate":-0.023097,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-28.89917,"latestTime":"04-21 15:24:53 EDT","open":1252.1276,"high":1257.6151,"low":1216.6044,"amount":3648654124.411469,"amplitude":0.032776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.286466,"peRate":32.45662,"turnoverRate":0.004168,"increases":3,"decrements":4,"flats":0,"marketCap":1303066869792,"floatMarketCap":1227444656672},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1257.6151,"amplitude":0.032776,"preClose":1251.235,"low":1216.6044,"pbRate":"9.286466","latestPrice":1222.345,"volume":44032524,"delay":0,"open":1252.1276,"prevYearClose":1305.0607,"prevWeekClose":1251.235,"prevMonthClose":1314.3724,"prevQuarterClose":1314.3724,"fiveDayClose":1177.7317,"twentyDayClose":1358.6935,"sixtyDayClose":1290.7499,"secType":"PLATE","market":"US","turnoverRate":0.004168,"peRate":32.45662,"marketCap":1302700425248,"floatMarketCap":1227072789024,"timestamp":1745263490747,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528364742","title":"European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2528364742","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528364742?lang=en_us&edition=fundamental","pubTime":"2025-04-17 23:05","pubTimestamp":1744902319,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were modestly higher late Thursday morning, rising 0.31% to 1,331.70 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and telecommunications company Ericsson , which rose 2.7% and 2.3% respectively. They were followed by biopharmaceutical company Cellectis  and telecommunications operator Telefonica , which were up 2.1% and 2% respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk  and furniture maker Natuzzi , which lost 8.3% and 3.2% respectively. They were followed by 3D printer company Materialise  and biopharmaceutical company Genfit , which dropped 2.4% and 1.8% respectively.From the UK and Ireland, the gainers were led by insurance company Prudential  and biotech firm Autolus Therapeutics , which increased 3.7% and 3.3% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group  a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4515","BK4201","BK4532","LU0162691827.USD","NTZ","BK4082","LU1162221912.USD","BK4139","GNFT","NVO","BK4546","LU1093756325.SGD","IE00BKVL7J92.USD","MREO","LU1829250122.USD","BDRX","BK4115","LU1093756168.USD","AKTX","BK4007","BK4117","AFG","LU0072461881.USD","BK4505","NCNA","BK4107","LU0154236417.USD","NVO.AU","BK4585","TEF","LU0320765646.SGD","CLLS","AMRN","BK4554","BK4591","BP","BK4162","BK4020","AUTL","EDAP","ERIC","BK4023","BK4599","PUK","BK4095","MTLS","IE00BZ1G4Q59.USD","BK7104","BK4588"],"gpt_icon":1},{"id":"2528459407","title":"Early notable gainers among liquid option names on April 17th","url":"https://stock-news.laohu8.com/highlight/detail?id=2528459407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528459407?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:55","pubTimestamp":1744898114,"startTime":"0","endTime":"0","summary":"Notable gainers among liquid option names this morning include Eli Lilly (LLY) $852.95 +118.05, Fidelity National Information Services (FIS) $73.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/early-notable-gainers-among-liquid-option-names-on-april-17th-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/early-notable-gainers-among-liquid-option-names-on-april-17th-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","LU1720051017.SGD","IE00B1BXHZ80.USD","IE0009355771.USD","LU0006061336.USD","LU1917777945.USD","LU1814569148.SGD","FIS","LU1861217088.USD","LU1720051108.HKD","LU0640476718.USD","LU0354030511.USD","LU2324357040.USD","LU2360107671.USD","GB00BDT5M118.USD","BK4516","IE00BK4W5L77.USD","LLY","LU1064131342.USD","LU1280957306.USD","BK4007","LU0128525689.USD","LU1868837136.USD","LU2237443895.HKD","LU1868836757.USD","LU0672654240.SGD","LU0094547139.USD","LU2360106947.USD","LU2468319806.SGD","LU2264538146.SGD","LU0238689110.USD","LU2750360641.GBP","LU0820561909.HKD","LU1712237335.SGD","LU0354030438.USD","LU2471134879.HKD","BK4599","LU1366192091.USD","LU2471134796.USD","LU0795875169.SGD","IE00BJT1NW94.SGD","LU2552382058.USD","SG9999014914.USD","LU0949170772.SGD","LU0061475181.USD","LU1023059063.AUD","SG9999017495.SGD","LU0943347566.SGD","LU0122379950.USD","LU0471298777.SGD"],"gpt_icon":0},{"id":"2528674596","title":"Eli Lilly rises 13.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528674596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528674596?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:50","pubTimestamp":1744897843,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) is up 13.0%, or $95.27 to $830.17. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-rises-13-0?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-rises-13-0?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1064131342.USD","LU1023059063.AUD","LU1720051108.HKD","LU1366192091.USD","LU1868836757.USD","BK4599","IE00BJT1NW94.SGD","LU0471298777.SGD","LU1917777945.USD","LU1712237335.SGD","LU0097036916.USD","LU2360106947.USD","LU2324357040.USD","LU2468319806.SGD","BK4007","LU0820561909.HKD","LU2552382058.USD","BK4516","LU0354030438.USD","LU1868837300.USD","LU2471134879.HKD","LU2237443895.HKD","LU1814569148.SGD","LU2471134796.USD","LU1280957306.USD","SG9999001176.SGD","IE00B1BXHZ80.USD","SG9999014914.USD","LU0672654240.SGD","LU1623119135.USD","LU2750360641.GBP","LU2264538146.SGD","LU0122379950.USD","LLY","LU0640476718.USD","LU0094547139.USD","LU1551013342.USD","LU0943347566.SGD","SG9999017495.SGD","GB00BDT5M118.USD","IE00BK4W5L77.USD","LU0061475181.USD","LU0354030511.USD","IE0009355771.USD","LU0203201768.USD","LU1868837136.USD","LU0238689110.USD","BK4533","LU1720051017.SGD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2528974512","title":"Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528974512","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528974512?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:45","pubTimestamp":1744897528,"startTime":"0","endTime":"0","summary":"In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private health insurance is the two leading causes of this increase.Impact of Tariffs on the US Healthcare Industry and China Relations. By automating procedures, fostering data connectivity, and producing actionable insights, technological innovation  keeps providing opportunities for stakeholders from all industries. McKinsey predicts that increased utilization and pipeline expansio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-inc-amgn-among-innovative-134528561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","QID","PSQ","TSYW.SI","IE00BFTCPJ56.SGD","SQQQ","BK4585","BK4599","SG9999001440.SGD","LU1057294990.SGD","IE0002141913.USD","LU1983299246.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","BK4137","BK4581","HCSG","IE00B2B36J28.USD","IYH","BK4139","BK4533","BK4534","BK4588","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1061106388.HKD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","IE0009355771.USD","LU0320765992.SGD","BK4566","LU1571399168.USD","QLD","IE00BJT1NW94.SGD","MNQmain","LU0289739699.SGD","USAW.SI","LU1023059063.AUD","LU0122379950.USD","TQQQ","NVIW.SI","NQmain","AMGN","LU0889565916.HKD",".IXIC","LU0058720904.USD"],"gpt_icon":1},{"id":"2528453887","title":"Unusually active option classes on open April 17th","url":"https://stock-news.laohu8.com/highlight/detail?id=2528453887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528453887?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:40","pubTimestamp":1744897219,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Energy Fuels (UUUU), Maplebear Inc (CART), Eli Lilly (LLY), Dollar General (DG), American Expr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-17th-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-17th-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GB00BDT5M118.USD","LLY","SG9999014914.USD","LU0354030438.USD","BK4504","BK4516","LU0238689110.USD","LU0943347566.SGD","LU2552382058.USD","IE00BJT1NW94.SGD","LU1868836757.USD","LU2324357040.USD","LU1720051108.HKD","LU2750360641.GBP","LU1280957306.USD","LU1720051017.SGD","LU1814569148.SGD","LU1989763427.SGD","LU0640476718.USD","LU1868837136.USD","LU2468319806.SGD","DG","LU2237438978.USD","LU1585245621.USD","LU2471134879.HKD","IE00B1BXHZ80.USD","UUUU","LU0471298777.SGD","BK4599","IE00BK4W5L77.USD","LU0094547139.USD","LU0672654240.SGD","LU1712237335.SGD","LU2237443895.HKD","LU2471134796.USD","LU0122379950.USD","BK4007","LU1064131342.USD","LU1917777945.USD","BK4155","IE0009355771.USD","BK4533","LU1989763690.USD","LU1023059063.AUD","LU1366192091.USD","LU0061475181.USD","SG9999017495.SGD","LU0820561909.HKD","LU2264538146.SGD","CART"],"gpt_icon":0},{"id":"2528797875","title":"Eli Lilly Shares Soar 14% as Lilly Pill Leads To 7.9% Weight Loss In Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797875","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797875?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:34","pubTimestamp":1744896844,"startTime":"0","endTime":"0","summary":"","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA73V7TJ:8","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Lilly Pill Leads To 7.9% Weight Loss At 40 Weeks In Trial","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0466842654.USD","LU1366192091.USD","LU0417517546.SGD","SG9999001176.SGD","LU0058720904.USD","LU0097036916.USD","LU0320765059.SGD","LU1814569148.SGD","BK4516","LU0114720955.EUR","LU2552382215.SGD","LU0122379950.USD","IE00B1BXHZ80.USD","LU0820561818.USD","SGXZ51526630.SGD","NVO","SG9999001176.USD","LU2491049909.HKD","LU0109391861.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","LU2471134523.USD","LU2361044865.SGD","LU0354030438.USD","LU2265009873.SGD","LU1061106388.HKD","LU0256863902.USD","SGXZ99366536.SGD","LU2237443622.USD","SG9999015945.SGD","SG9999015952.SGD","LLY","LU1267930730.SGD","LU2750360997.AUD","LU1551013425.SGD","LU2360106947.USD","LU0385154629.USD","SG9999017495.SGD","LU0456855351.SGD","BK4599","LU2602419157.SGD","LU0289739699.SGD","LU0882574055.USD","LU1868836914.USD","LU1868836591.USD","LU2361045086.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2237443549.SGD","LU1983299246.USD","LU0354030511.USD"],"gpt_icon":1},{"id":"2528674819","title":"Shares of Some Obesity Drug Developers Fall After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528674819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528674819?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:33","pubTimestamp":1744896814,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2242652126.USD","BK4534","LU1057294990.SGD","BK4581","LU1023059063.AUD","BK4566","AMGN","LU1571399168.USD","BK4585","LU1983299246.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0058720904.USD","LU2112291526.USD","BK4533","BK4599","LU2089984988.USD","IE00B2B36J28.USD","LU0109394709.USD","LU0889565916.HKD","BK4139","LU1061106388.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","IE00BJJMRZ35.SGD","VKTX","LU0122379950.USD","IE0002141913.USD","SG9999001440.SGD","LU0868494617.USD","BK4588","LU0320765992.SGD","LU2468319806.SGD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2528174842","title":"U.S.-Listed Shares of Novo Nordisk Down 7.9%, Viking Therapeutics Down 3.9%, Amgen Down 3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528174842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528174842?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:33","pubTimestamp":1744896814,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1AE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1983299246.USD","IE00BJJMRZ35.SGD","BK4599","BK4581","LU1023059063.AUD","IE0002141913.USD","LU2242652126.USD","LU2242646821.SGD","LU0058720904.USD","LU0889565916.HKD","LU2468319806.SGD","VKTX","IE00B2B36J28.USD","BK4585","LU0320765992.SGD","LU0868494617.USD","LU0122379950.USD","BK4588","IE00B4R5TH58.HKD","BK4566","IE0009355771.USD","LU1571399168.USD","LU2112291526.USD","BK4139","AMGN","LU2089984988.USD","BK4534","BK4533","IE00BJT1NW94.SGD","LU1061106388.HKD","LU0109394709.USD","SG9999001440.SGD","LU1057294990.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2528671237","title":"BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528671237","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528671237?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:53","pubTimestamp":1744894413,"startTime":"0","endTime":"0","summary":"BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trialUpdates** Shares of drugmaker Eli Lilly LLY.N rise 12.7% to $828.67 premarket** Company says its small molecule oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial** Shares of Structure Therapeutics GPCR.O, which is also developing a small molecule oral weight loss drug, gain 17.7% before the bell** U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 6%** Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 5.1% and Amgen AMGN.O down 2.8%** Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nL4N3QV176:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","LU0882574139.USD","LU0820561818.USD","LU1868836914.USD","IE0009355771.USD","LU2491050154.USD","GPCR","LU2237443978.SGD","BK4599","LU2237438978.USD","SG9999014906.USD","LU1548497426.USD","LU2750360997.AUD","SGXZ31699556.SGD","LU2357305700.SGD","LU1093756325.SGD","AMGN","SG9999001440.SGD","LU1720051108.HKD","LU0889565916.HKD","LU0943347566.SGD","LU1093756168.USD","LU0203202063.USD","BK4533","SGXZ51526630.SGD","LU2360106947.USD","LU2237443622.USD","LU1551013425.SGD","LU2468319806.SGD","VKTX","LU0122379950.USD","LU0417517546.SGD","LU0058720904.USD","LU0106261372.USD","LU0256863811.USD","SGXZ99366536.SGD","LU1366192091.USD","LU1057294990.SGD","LLY","LU0289739699.SGD","LU2242646821.SGD","LU0096364046.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1988902786.USD","LU0820561909.HKD","LU2361044865.SGD","SG9999014898.SGD","LU0109391861.USD"],"gpt_icon":1},{"id":"2528802715","title":"Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528802715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528802715?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:42","pubTimestamp":1744890170,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2528718715","title":"Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2528718715","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528718715?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:24","pubTimestamp":1744889040,"startTime":"0","endTime":"0","summary":"Eli Lilly stock was soaring Thursday after the pharmaceutical company said it had successfully completed a trial of a new weight-loss pill.Shares jumped 11% to $817 in premarket trading. Futures tracking the benchmark S&P 500 were up 0.5%.The surge came after Mounjaro and Zepbound developer Lilly said it had completed a Phase 3 trial for its orforglipron pill. The trial showed that the pill is safe to a level comparable with injectable weight-loss drugs.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","SG9999014898.SGD","LU1712237335.SGD","IE0002141913.USD","LU2211815571.USD","LU0256863811.USD","IE00BK4W5M84.HKD","LU2063271972.USD","LU2602419157.SGD","SGXZ57979304.SGD","LU1720051108.HKD","LLY","LU1623119135.USD","MMAT","LU2468319806.SGD","LU0354030511.USD","LU1061106388.HKD","LU0640476718.USD","SG9999017495.SGD","LU1868836757.USD","LU2237443382.USD","LU0256863902.USD","SG9999015945.SGD","IE0004445239.USD","LU1232071149.USD","IE00B2B36J28.USD","LU0106261372.USD","LU2361044865.SGD","BK4533","LU0061475181.USD","LU2106854487.HKD","LU0417517546.SGD","LU1023059063.AUD","LU1064131342.USD","LU0058720904.USD","LU2360106947.USD","LU0079474960.USD","LU2491050071.SGD","SG9999014914.USD","LU2471134523.USD","BK4007","LU0198837287.USD","BK4599","LU1551013342.USD","LU2471134879.HKD","BK4141","LU2491049909.HKD","BK4516","LU2324357040.USD","LU0203202063.USD"],"gpt_icon":1},{"id":"2528718548","title":"Eli Lilly's Stock Soars 13% After Reporting Positive Data From Trial Of Diabetes And Weight-Loss Pill -- MarketWatch","url":"https://stock-news.laohu8.com/highlight/detail?id=2528718548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528718548?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:15","pubTimestamp":1744888500,"startTime":"0","endTime":"0","summary":"Eli Lilly & Co.'s Inc.'s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.The company   said orforglipron showed statistically significant results and a safety profile that was consistent with injectable GLP-1 medicines in the Phase 3 trial. The once-daily treatment reduced weight by an average of 16 lbs at the highest dose in a secondary endpoint.The drug is the first oral small-molecule GLP-receptor agonist to successfully complete a Phase 3 trial, said Lilly in a statement.\"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year,\" said Lilly CEO David A. Ricks in prepared remarks.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1712237335.SGD","IE00BJLML261.HKD","LU0943347566.SGD","BK4533","LU0672654240.SGD","LU2211815571.USD","SG9999014880.SGD","BK4581","LU2461242641.AUD","SGXZ99366536.SGD","LU1093756325.SGD","LU1267930730.SGD","LU2471134796.USD","LU0238689110.USD","LU1983299246.USD","GB00BDT5M118.USD","SGXZ31699556.SGD","SG9999018857.SGD","LU0820561909.HKD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU2471134952.CNY","BK4534","LU0198837287.USD","SG9999015945.SGD","LLY","IE00B1BXHZ80.USD","LU1868836591.USD","LU2063271972.USD","LU2602419157.SGD","LU0079474960.USD","BK4516","BK4599","LU2237438978.USD","LU0106261372.USD","LU0417517546.SGD","LU1551013425.SGD","SG9999015986.USD","LU0109391861.USD","LU0058720904.USD","LU0289739699.SGD","LU0882574139.USD","LU1061106388.HKD","SG9999001176.USD","LU2491050071.SGD","LU1814569148.SGD","LU0006306889.USD","LU1366192091.USD","LU0640476718.USD"],"gpt_icon":1},{"id":"2528718515","title":"Eli Lilly's stock soars 13% after reporting positive data from trial of diabetes and weight-loss pill","url":"https://stock-news.laohu8.com/highlight/detail?id=2528718515","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528718515?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:15","pubTimestamp":1744888500,"startTime":"0","endTime":"0","summary":"Eli Lilly & Co.'s Inc.'s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.The company   said orforglipron showed statistically significant results and a safety profile that was consistent with injectable GLP-1 medicines in the Phase 3 trial. The once-daily treatment reduced weight by an average of 16 lbs at the highest dose in a secondary endpoint.The drug is the first oral small-molecule GLP-receptor agonist to successfully complete a Phase 3 trial, said Lilly in a statement.\"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year,\" said Lilly CEO David A. Ricks in prepared remarks.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1061106388.HKD","LU1267930730.SGD","SG9999015986.USD","LU0672654240.SGD","LU2063271972.USD","BK4599","LU1712237335.SGD","LU0109391861.USD","LU1983299246.USD","SG9999014880.SGD","GB00BDT5M118.USD","LU0106261372.USD","LU1093756168.USD","SGXZ31699556.SGD","LU0640476718.USD","LU2237438978.USD","LU2471134952.CNY","LU1366192091.USD","SG9999018857.SGD","IE00B1BXHZ80.USD","BK4534","LU0238689110.USD","SGXZ99366536.SGD","SG9999015945.SGD","LU1814569148.SGD","LLY","IE00BJT1NW94.SGD","LU0198837287.USD","BK4516","LU1868836591.USD","LU2461242641.AUD","LU2491050071.SGD","LU2602419157.SGD","LU0058720904.USD","BK4581","LU0417517546.SGD","LU1551013425.SGD","LU2471134796.USD","LU0006306889.USD","IE00B4R5TH58.HKD","IE00BJLML261.HKD","LU0079474960.USD","BK4533","LU2211815571.USD","LU0820561909.HKD","LU0882574139.USD","SG9999001176.USD","LU0943347566.SGD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2528790978","title":"Novo Nordisk : Bmo Cuts to Market Perform From Outperform; Cuts Target Price to $64 From $105","url":"https://stock-news.laohu8.com/highlight/detail?id=2528790978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528790978?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:06","pubTimestamp":1744887980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV22T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0154236417.USD","NVO","LU1093756168.USD","BK4532","LU1093756325.SGD","BK4599","BK4585","BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":0},{"id":"2528797779","title":"Eli Lilly announces ACHIEVE-1 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797779","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797779?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:55","pubTimestamp":1744887343,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-announces-achieve-1-trial-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-announces-achieve-1-trial-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LLY","LU2471134796.USD","LU0109391861.USD","SG9999015978.USD","LU0689472784.USD","LU2471134879.HKD","LU1093756168.USD","LU1720051017.SGD","LU0708995401.HKD","LU2552382215.SGD","LU0198837287.USD","BK4599","LU0385154629.USD","LU2324357040.USD","LU1280957306.USD","LU2237443622.USD","SGXZ99366536.SGD","LU0203201768.USD","SG9999001176.SGD","LU0882574139.USD","LU1623119135.USD","LU1712237335.SGD","IE00B2B36J28.USD","LU0256863811.USD","LU1868837300.USD","LU1804176565.USD","IE00BJLML261.HKD","LU0672654240.SGD","SG9999014898.SGD","SG9999015945.SGD","LU2237443978.SGD","LU1035775433.USD","LU0289739699.SGD","LU0882574055.USD","LU1868836591.USD","IE00BK4W5M84.HKD","LU1868836757.USD","IE00B4R5TH58.HKD","LU1983299246.USD","SG9999018857.SGD","LU2552382058.USD","LU2237443465.HKD","SG9999014880.SGD","IE00BFTCPJ56.SGD","BK4516","IE0009355771.USD","LU2112291526.USD","LU0079474960.USD","LU0456855351.SGD","BK4588"],"gpt_icon":0},{"id":"2528679719","title":"Diabetes Device Maker Dexcom Shares Down 3.1% Premarket After Lilly's Pill Leads to Weight Loss in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528679719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528679719?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:55","pubTimestamp":1744887343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nL4N3QV0ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0061475181.USD","LU2552382132.HKD","IE00BFTCPJ56.SGD","DXCM","LU0203202063.USD","LU2237443382.USD","LU1366192091.USD","LU2491050154.USD","LU1974910355.USD","LU2237438978.USD","LU0820561818.USD","LU0114720955.EUR","LU0109391861.USD","LU1280957306.USD","LU1989771016.USD","LU2265009873.SGD","LU0943347566.SGD","LU0708995401.HKD","LU2491050071.SGD","SG9999018865.SGD","LLY","LU2089984988.USD","BK4533","BK4534","LU2357305700.SGD","LU0640476718.USD","LU0882574139.USD","LU1720051017.SGD","SG9999014880.SGD","SGXZ51526630.SGD","LU0238689110.USD","LU2106854487.HKD","BK4599","SG9999015986.USD","LU0320765059.SGD","SG9999015952.SGD","GB00BDT5M118.USD","LU0823416689.USD","LU0471298777.SGD","SGXZ99366536.SGD","LU2461242641.AUD","LU2552382215.SGD","LU1267930730.SGD","LU0203201768.USD","LU2125909247.SGD","LU0256863902.USD","SGXZ57979304.SGD","LU2433249047.HKD","IE0004445239.USD","LU2552382058.USD"],"gpt_icon":0},{"id":"2528797607","title":"Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797607","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797607?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:51","pubTimestamp":1744887089,"startTime":"0","endTime":"0","summary":"Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0061475181.USD","IE00BJT1NW94.SGD","LU2552382132.HKD","IE00BFTCPJ56.SGD","LU0466842654.USD","LU0203202063.USD","LU2237443382.USD","LU0471298694.HKD","LU1868837300.USD","LU1974910355.USD","LU2237438978.USD","LU1868836591.USD","LU0820561818.USD","LU1057294990.SGD","LU1868836757.USD","LU1989771016.USD","LU2237443978.SGD","LU2237443622.USD","LU0689472784.USD","LU0289739699.SGD","LU0943347566.SGD","LU0708995401.HKD","LLY","BK4533","BK4534","LU1868836914.USD","LU1868837136.USD","LU2237443549.SGD","IE00B1BXHZ80.USD","LU0106261372.USD","LU0820561909.HKD","LU1093756325.SGD","LU0882574139.USD","LU1720051017.SGD","LU2264538146.SGD","SG9999014880.SGD","BK4599","SG9999015986.USD","LU0320765059.SGD","LU0823416689.USD","SG9999018857.SGD","LU2552382215.SGD","LU0097036916.USD","LU1061106388.HKD","LU0203201768.USD","LU2023250504.SGD","SGXZ57979304.SGD","LU0122379950.USD","IE0004445239.USD","LU2552382058.USD"],"gpt_icon":0},{"id":"2528153347","title":"Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2528153347","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528153347?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886726,"startTime":"0","endTime":"0","summary":"Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.In March this year, U.S. pharma giant Eli Lilly And Co  announced the launch of its popular weight loss drug Mounjaro  in India, which is expected to have the second-largest population of overweight or obese people by 2050.Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!See Also: This investment company boasts a 33.85% internal rate of return  for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.Lakdawala also said Eli Lilly will have an early lead over Novo Nordisk’s Wegovy. Wegovy contains semaglutide, the same ingredient as its diabetes drug Ozempic—a medication often used off-label for weight loss.Novo may also have to price Wegovy more competitively in India. Mounjaro, a once-weekly injection approved by Indi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lillys-mounjaro-launch-triggers-104526470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IRR","LU1280957306.USD","SG9999014906.USD","LU1804176565.USD","IE00BK4W5L77.USD","LU1057294990.SGD","BK4516","BK4581","LU2357305700.SGD","LU1712237335.SGD","LU0256863902.USD","LU1093756168.USD","SG9999015952.SGD","LU1983299246.USD","LU2023250504.SGD","IE00BFTCPJ56.SGD","SG9999018857.SGD","LU2106854487.HKD","LU0289739699.SGD","LU2112291526.USD","LU2265009873.SGD","LU1868837300.USD","LU2471134523.USD","BK4533","LU1093756325.SGD","LLY","BK4599","IE00B2B36J28.USD","LU1551013342.USD","LU0094547139.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU0203201768.USD","LU0466842654.USD","NVO","SGXZ99366536.SGD","SG9999014880.SGD","LU1267930730.SGD","LU2264538146.SGD","LU1291159041.SGD","SG9999017495.SGD","SG9999015945.SGD","IE00BKVL7J92.USD","LU2324357040.USD","IE00B4R5TH58.HKD","IE00BJLML261.HKD","LU2552382132.HKD","LU0256863811.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2528797874","title":"Eli Lilly - Expects to Submit Orforglipron for Weight Management, Submission for Treatment of Type 2 Diabetes Anticipated in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797874?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA73V7TJ:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2361045086.USD","SG9999001176.SGD","LU0256863902.USD","LU0385154629.USD","LLY","LU2468319806.SGD","SG9999001176.USD","LU0122379950.USD","LU0820561818.USD","LU0354030511.USD","LU1814569148.SGD","LU0320765059.SGD","LU2237443549.SGD","LU2750360997.AUD","BK4516","IE00B1BXHZ80.USD","LU1868836591.USD","LU0109391861.USD","LU0097036916.USD","LU1366192091.USD","IE00BJJMRZ35.SGD","SGXZ99366536.SGD","LU2237443622.USD","LU1093756325.SGD","SGXZ51526630.SGD","BK4599","IE00B4R5TH58.HKD","LU1551013425.SGD","LU2491049909.HKD","LU1267930730.SGD","LU1868836914.USD","LU0289739699.SGD","LU2265009873.SGD","SG9999015952.SGD","LU2360106947.USD","LU2471134523.USD","SG9999017495.SGD","LU2602419157.SGD","LU0456855351.SGD","SG9999015945.SGD","LU1061106388.HKD","LU2361044865.SGD","LU0058720904.USD","LU0466842654.USD","LU1983299246.USD","LU0354030438.USD","LU0882574055.USD","LU0417517546.SGD","LU2552382215.SGD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2528373790","title":"Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528373790","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528373790?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886700,"startTime":"0","endTime":"0","summary":"Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses. The overall safety and tolerability profile oforforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies. In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand.2 In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, which is below the American Diabetes Association's  defined threshold for diabetes.3 In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs  at the highest dose. Given that participants had not yet reached a weight plateau at the time the study ended, it appears that full weight reduction was not ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500810.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","LU0820561818.USD","LU1232071149.USD","BK4144","LU2552382058.USD","LU0882574055.USD","LU0289739699.SGD","LLY","LU1551013425.SGD","IE00B1BXHZ80.USD","LU0061475181.USD","IE00BK4W5L77.USD","LU2264538146.SGD","LU0820561909.HKD","SG9999015978.USD","LU2361044949.HKD","LU2237438978.USD","LU2602419157.SGD","SGXZ81514606.USD","LU0882574139.USD","SGXZ31699556.SGD","SGXZ99366536.SGD","LU2237443465.HKD","LU2237443978.SGD","SG9999015945.SGD","BK4590","LU1868836591.USD","LU0238689110.USD","LU0097036916.USD","LU0096364046.USD","LU1061106388.HKD","LU1712237335.SGD","IE00BJLML261.HKD","LU0198837287.USD","LU0354030511.USD","GLP","LU2491050071.SGD","LU0417517546.SGD","LU2023250504.SGD","SGXZ51526630.SGD","BK4585","LU2112291526.USD","LU0640476718.USD","LU0094547139.USD","LU2750360641.GBP","BK4599","SG9999014880.SGD","LU2324357040.USD","LU1983299246.USD","LU1280957306.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":153,"code":"91000000","status":"200"}]}}